Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions
Year: 2020
Type: article
Abstract: Biological agents (BA) are emerging as potential effective treatment for allergic and hypersensitivity disorders (A/H). Four main classes of BA are now (May 2020) approved by US Food and Drug Administration and European Medicines Agency for A/H: anti-IgE (omalizumab),1 anti-IL5 (mepolizumab, reslizumab),2 anti-IL4/13 (dupilumab),3 and anti-IL5R (benralizumab).4 Hypersensitivity reactions (HSR) due to BA can occur with different severity degrees, which hamper their use. New types of HSR have been reported with lack of standardized and guided allergy workup.
Authors: Leyla Barakat, Maria Jose Torres, Elizabeth J. Phillips, Marco Caminati, Yoon-Seok Chang, Davide Caimmi, Mario Sanchez-Borges, Lanny Rosenwasser, Alain Didier, Frédéric de Blay, Jean-François Fontaine, Isabelle Bosse, Sebastien Lefevre, Cintia Bassani, Maria De Filippo, Igancio Asontegui, Mario Morais-Almeida, Motohiro Ebisawa, Bryan Martin, Bernard Yu-Hor Thong, Pascal Demoly, Luciana Kase Tanno
Institutions: Centre Hospitalier Universitaire de Montpellier, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Murdoch University, Vanderbilt University, Vanderbilt University Medical Center, University of Verona, Seoul National University, Seoul National University Bundang Hospital, Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Centro Médico Docente La Trinidad, Children's Mercy Hospital, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Centre de Physiopathologie de Toulouse-Purpan, Hôpital Larrey, Hôpital Purpan, Hôpitaux Universitaires de Strasbourg, Centre Hospitalier Universitaire de Reims, Centre Hospitalier Régional de Metz-Thionville, Atitus Educação, University of Pavia, Policlinico San Matteo Fondazione, IDCQ Hospitales y Sanidad, S.L.U., Hospital CUF Descobertas, National Sagamihara Hospital, The Ohio State University, Tan Tock Seng Hospital, Institut Universitaire de Recherche Clinique, Institut Desbrest d'Epidémiologie et de Santé Publique
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,400
Funder: Novartis
OpenAlex ID: W3096592787